Abstract
Guttate psoriasis is an eruptive variant of plaque psoriasis. Systemic therapy of guttate psoriasis has been inconsistently effective. Given that guttate psoriasis and plaque psoriasis share several immunopathogenic features, we hypothesized that antibodies targeting interleukin-17 (IL-17) would be effective in the treatment of guttate psoriasis. Here we present a series of 3 patients with guttate psoriasis successfully treated with ixekizumab, a monoclonal antibody against IL-17A.
Get full access to this article
View all access options for this article.
